COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00524667
Recruitment Status : Terminated (Terminated due to poor accrual.)
First Posted : September 3, 2007
Last Update Posted : July 20, 2011
The Leukemia and Lymphoma Society
Information provided by:
CancerCare Manitoba

Brief Summary:


To investigate:

  • the mechanism of Valproic Acid (VPA)-induced apoptosis in B-CLL
  • the ability of VPA in combination with standard chemotherapy or new antitumor agents to induce a synergistic antitumor effect in chronic lymphocytic leukemia (CLL) cells
  • the clinical efficacy of VPA in previously treated CLL patients.

This will be an example of a translational research study where the results of our laboratory studies will be applied to a clinical trial in the CLL clinic at CancerCare Manitoba.

Condition or disease Intervention/treatment Phase
Chronic Lymphocytic Leukemia Drug: Valproic acid & fludarabine Phase 2

Detailed Description:

All participants will be treated with valproic acid (VPA) at a starting dose of 15 mg/kg/day orally in divided doses. This dose produces a VPA plasma level of 346-693 μM and is the recommended starting dose for patients with seizure disorder. Each week a pre-dose serum VPA level will be determined by immunoassay and the daily dose increased by 5 mg/kg/d to ensure a predose level > 1mM. Once the target dose has been achieved serum VPA levels will be determined on a monthly basis to ensure a pre dose level >1mM.

After completing 28 days of therapy participants will be examined and have lab work drawn (CBC with differential, electrolytes, BUN, creatinine, total protein, albumin, calcium, LDH, total and direct bilirubin, ALT/AST, and β2-microglobulin. Females of child bearing age will undergo a pregnancy test prior to each 28 day cycle). For participants identified as having stable or progressive disease (National Cancer Institute Criteria), Fludarabine (Flu) therapy will be added to VPA on a 28 day cycle. Oral Flu will be administered at a dose of 40 mg/m2/day on days 1-3 of a 28 day cycle in addition to VPA as described above. Dose adjustments for Flu will be based on creatinine clearance. All participants receiving fludarabine will receive irradiated blood products and pneumocystis carnii prophylaxis.

Treatment will be continued with VPA ± Flu to a maximum of six 28 day cycles. Therapy will be discontinued prior to six 28 day cycles if: a) the participant requests discontinuation, b) if the participant is unable to comply with the protocol, c) the medical care team thinks a change of therapy would be in the best interest of the participant, d) there is evidence of progressive disease after two cycles of VPA + Flu, e) if the participant experiences unacceptable toxicity attributable to the study drugs such as ≥3 non-hematological toxicity or prolonged grade 4 hematological toxicity (NCI common toxicity criteria, Table 5 of the protocol), f) if the AST/ALT increase to > 6x the upper limit of normal or g) the participant becomes pregnant.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia
Study Start Date : January 2008
Actual Primary Completion Date : July 2011
Actual Study Completion Date : July 2011

Arm Intervention/treatment
Experimental: 1 Drug: Valproic acid & fludarabine
valproic acid (VPA) starting dose of 15 mg/day p.o. in divided doses, increased weekly by 5 mg/kg/day until >1mM Fludarabine 40 mg/m2/day orally will be added after completing 28 days of VPA if participant has been identified as having stable or progressive disease.

Primary Outcome Measures :
  1. Best clinical response as defined by NCIWG criteria for CLL [ Time Frame: 6 months after commencing therapy ]

Secondary Outcome Measures :
  1. Effect of treatment on histone acetylation status; hematological toxicity (graded according to NCIWG criteria for CLL) and nonhematological toxicity (graded according to NCI common toxicity criteria) [ Time Frame: throughout therapy ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Active CLL (as defined by the National Cancer Institute Working Group)
  • Patients must have received at least one prior therapy for CLL and have been treated with a nucleoside analogue.
  • Recruitment will be limited to those with an ECOG performance status of 2 or less.

Exclusion Criteria:

  • Patients who are pregnant or breastfeeding
  • Patients with a history of autoimmune cytopenias
  • Patients with platelets < 50 x 109/L or an absolute neutrophil count < 1.5X109/L
  • Patients with hepatic disease or an AST/ALT 6x above the upper limit of normal
  • Patients with a calculated creatinine clearance < 30 ml/min using the Cockroft and Gault formula
  • Patients with a history of pancreatitis
  • Patients who are receiving drugs that affect VPA protein binding or metabolism
  • Patients with active infection, HIV or active viral hepatitis
  • Patients with active secondary malignancy or who have central nervous system involvement with CLL
  • Patients diagnosed with more an aggressive lymphoproliferative disorder such as Richter's transformation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00524667

Layout table for location information
Canada, Manitoba
CancerCare Manitoba
Winnipeg, Manitoba, Canada, R3E 0V9
Sponsors and Collaborators
CancerCare Manitoba
The Leukemia and Lymphoma Society
Layout table for investigator information
Principal Investigator: David Szwajcer, MD CancerCare Manitoba / University of Manitoba

Additional Information:
Layout table for additonal information
Responsible Party: Dr. David Szwajcer, Principal Investigator, CancerCare Manitoba Identifier: NCT00524667    
Other Study ID Numbers: CCM-001
First Posted: September 3, 2007    Key Record Dates
Last Update Posted: July 20, 2011
Last Verified: July 2011
Keywords provided by CancerCare Manitoba:
Active CLL
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Valproic Acid
Antineoplastic Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Enzyme Inhibitors
GABA Agents
Neurotransmitter Agents
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs